Median time to pain improvement and the impact of baseline pain severity on pain response in patients with psoriatic arthritis treated with tofacitinib

Median time to pain improvement and the impact of baseline pain severity on pain response in patients with psoriatic arthritis treated with tofacitinib

<br><strong>Background </strong>Pain is a core domain of psoriatic arthritis (PsA). This post hoc analysis evaluated time to pain improvement and the impact of baseline pain severity on pain response in patients with PsA receiving tofacitinib. <br><strong> Methods </...

書誌詳細
主要な著者:	de Vlam, K, Ogdie, A, Bushmakin, AG, Cappelleri, JC, Fleischmann, R, Taylor, PC, Azevedo, V, Fallon, L, Woolcott, J, Mease, PJ
フォーマット:	Journal article
言語:	English
出版事項:	BMJ Publishing Group 2021

類似資料

Median time to pain improvement in patients with psoriatic arthritis treated with tofacitinib
著者:: de Vlam, K, 等
出版事項: (2018)

Baseline pain severity as a predictor of pain improvement following treatment with tofacitinib in psoriatic arthritis
著者:: Ogdie, A, 等
出版事項: (2018)

Identifying and quantifying the role of inflammation in pain reduction for patients with psoriatic arthritis treated with tofacitinib: a mediation analysis
著者:: de Vlam, K, 等
出版事項: (2022)

Understanding mediators of pain reduction in psoriatic arthritis patients treated with tofacitinib: role of inflammation
著者:: Taylor, P, 等
出版事項: (2019)

Identifying mediators of pain reduction in patients with psoriatic arthritis treated with tofacitinib: Role of inflammation associated with peripheral arthritis, enthesitis and skin disease
著者:: Taylor, PC, 等
出版事項: (2020)

The effect of tofacitinib on residual pain in patients with psoriatic arthritis
著者:: Dougados, M, 等
出版事項: (2020)

Efficacy of tofacitinib in reducing pain in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis
著者:: Iain B McInnes, 等
出版事項: (2020-02-01)

The effect of tofacitinib on residual pain in patients with rheumatoid arthritis and psoriatic arthritis
著者:: Dougados, M, 等
出版事項: (2022)

The effect of tofacitinib on residual pain in patients with rheumatoid arthritis and psoriatic arthritis
著者:: Maxime Dougados, 等
出版事項: (2022-11-01)

Time to response for clinical and patient-reported outcomes in patients with psoriatic arthritis treated with tofacitinib, adalimumab, or placebo
著者:: Gladman, DD, 等
出版事項: (2022)

Itch as major mediator of effect of tofacitinib on health-related quality of life in psoriatic arthritis: a mediation analysis
著者:: Taylor, PC, 等
出版事項: (2021)

Relationships between psoriatic arthritis composite measures of disease activity with patient-reported outcomes in Phase 3 studies of tofacitinib
著者:: Coates, L, 等
出版事項: (2021)

Pain and inflammation as mediators of tofacitinib treatment effect on fatigue in patients with ankylosing spondylitis: a mediation analysis
著者:: Kristensen, LE, 等
出版事項: (2023)

Effectiveness of Tofacitinib in Patients Initiating Therapy for Psoriatic Arthritis: Results from the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry
著者:: Philip J. Mease, 等
出版事項: (2024-01-01)

Relationships of dermatologic symptoms and quality of life in patients with psoriatic arthritis: analysis of two tofacitinib phase III studies
著者:: Taylor, P, 等
出版事項: (2022)

Impact of baseline body mass index on the efficacy and safety of tofacitinib in patients with psoriatic arthritis
著者:: Daniela Graham, 等
出版事項: (2021-04-01)

Time to response for clinical and patient-reported outcomes in patients with psoriatic arthritis treated with tofacitinib, adalimumab, or placebo
著者:: Dafna D. Gladman, 等
出版事項: (2022-02-01)

Relationships between psoriatic arthritis composite measures of disease activity with patient-reported outcomes in phase 3 studies of tofacitinib
著者:: Laura C. Coates, 等
出版事項: (2021-03-01)

Relationships of dermatologic symptoms and quality of life in patients with psoriatic arthritis: analysis of two tofacitinib phase III studies
著者:: Peter C. Taylor, 等
出版事項: (2022-07-01)

Measuring outcomes in psoriatic arthritis
著者:: Ogdie, A, 等
出版事項: (2020)

Efficacy and Safety of Tofacitinib in Patients with Psoriatic Arthritis or Ankylosing Spondylitis by Cigarette Smoking Status
著者:: Alexis Ogdie, 等
出版事項: (2024-09-01)

Pain and Inflammation as Mediators of Tofacitinib Treatment Effect on Fatigue in Patients with Ankylosing Spondylitis: A Mediation Analysis
著者:: Lars Erik Kristensen, 等
出版事項: (2023-06-01)

Tofacitinib as monotherapy following methotrexate withdrawal in patients with psoriatic arthritis previously treated with open-label tofacitinib plus methotrexate: a randomised, placebo-controlled substudy of OPAL Balance
著者:: Nash, P, 等
出版事項: (2020)

Psoriatic arthritis
著者:: FitzGerald, O, 等
出版事項: (2021)

Time to improvement of pain, morning stiffness, fatigue, and disease activity in patients with ankylosing spondylitis treated with tofacitinib: a post hoc analysis
著者:: Victoria Navarro-Compán, 等
出版事項: (2024-05-01)

Inhibition of interleukin-17 in patients with oligoarticular psoriatic arthritis
著者:: Ogdie, A, 等
出版事項: (2023)

Psoriatic arthritis - Tofacitinib as a new treatment
著者:: Marta Skorupska, 等
出版事項: (2024-06-01)

Pain reduction in patients with rheumatoid arthritis receiving tofacitinib monotherapy with or without pain medication: A post hoc analysis of pooled data from phase 2, phase 3 and phase 3B/4 studies
著者:: Taylor, PC, 等
出版事項: (2019)

Tofacitinib or adalimumab versus placebo: patient-reported outcomes from OPAL Broaden—a phase III study of active psoriatic arthritis in patients with an inadequate response to conventional synthetic disease-modifying antirheumatic drugs
著者:: Philip J Mease, 等
出版事項: (2019-06-01)

Effect of tofacitinib on patient-reported outcomes in patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors in the phase III, randomised controlled trial: OPAL Beyond
著者:: Philip J Mease, 等
出版事項: (2019-06-01)

Itch as the major mediator of the effect of tofacitinib on health-related quality of life in PSA: a mediation analysis
著者:: Taylor, P, 等
出版事項: (2020)

Influenza Adverse Events in Patients with Rheumatoid Arthritis, Ulcerative Colitis, or Psoriatic Arthritis in the Tofacitinib Clinical Development Programs
著者:: Kevin L. Winthrop, 等
出版事項: (2022-12-01)

Association between baseline cardiovascular risk and incidence rates of major adverse cardiovascular events and malignancies in patients with psoriatic arthritis and psoriasis receiving tofacitinib
著者:: Lars E. Kristensen, 等
出版事項: (2023-02-01)

Safety and efficacy of tofacitinib up to 48 months in patients with active psoriatic arthritis: final analysis of the OPAL Balance long-term extension study
著者:: Nash, P, 等
出版事項: (2021)

Post-marketing safety surveillance of tofacitinib over 9 years in patients with psoriatic arthritis and rheumatoid arthritis
著者:: Burmester, GR, 等
出版事項: (2023)

Tofacitinib in the management of active psoriatic arthritis: patient selection and perspectives
著者:: Ly K, 等
出版事項: (2019-08-01)

Efficacy of tofacitinib for the treatment of psoriatic arthritis: pooled analysis of two phase 3 studies
著者:: Nash, P, 等
出版事項: (2018)

Post-Marketing Safety Surveillance of Tofacitinib over 9 Years in Patients with Psoriatic Arthritis and Rheumatoid Arthritis
著者:: Gerd R. Burmester, 等
出版事項: (2023-07-01)

Efficacy of Tofacitinib for the Treatment of Psoriatic Arthritis: Pooled Analysis of Two Phase 3 Studies
著者:: Peter Nash, 等
出版事項: (2018-11-01)

Classification and outcome measures for psoriatic arthritis
著者:: Leung, Y, 等
出版事項: (2018)